# Bruce R. Blazar

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/bruce-r-blazar/

## Facts

| Field | Value |
| --- | --- |
| Citations | 92,024 |
| Field | Hematopoietic Stem Cell Transplantation |
| h-index | 149 |
| i10-index | 766 |
| Last Known Institution | University of Minnesota |
| OpenAlex ID | https://openalex.org/A5058268746 |
| ORCID iD | https://orcid.org/0000-0002-9608-9841 |
| Works | 1,517 |

## Researcher papers

- [Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer](https://scholariq.org/papers/successful-adoptive-transfer-and-in-vivo-expansion-of-human-haploidentical-nk/)
- [Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival](https://scholariq.org/papers/transplantation-of-unrelated-donor-umbilical-cord-blood-in-102-patients-with/)
- [Ibrutinib for chronic graft-versus-host disease after failure of prior therapy](https://scholariq.org/papers/ibrutinib-for-chronic-graft-versus-host-disease-after-failure-of-prior-therapy/)
- [Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation](https://scholariq.org/papers/composite-end-point-of-graft-versus-host-disease-free-relapse-free-survival/)
- [Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study](https://scholariq.org/papers/belumosudil-for-chronic-graft-versus-host-disease-after-2-or-more-prior-lines-of/)
- [A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality](https://scholariq.org/papers/a-refined-risk-score-for-acute-graft-versus-host-disease-that-predicts-response/)
- [TALEN-based Gene Correction for Epidermolysis Bullosa](https://scholariq.org/papers/talen-based-gene-correction-for-epidermolysis-bullosa/)
- [Oncogenic JAK2 <sup>V617F</sup> causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms](https://scholariq.org/papers/oncogenic-jak2-sup-v617f-sup-causes-pd-l1-expression-mediating-immune-escape-in/)
- [Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation](https://scholariq.org/papers/repression-of-the-genome-organizer-satb1-in-regulatory-t-cells-is-required-for/)
- [Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases](https://scholariq.org/papers/evaluation-of-tcr-gene-editing-achieved-by-talens-crispr-cas9-and-megatal/)

## Researcher topics

- [Hematopoietic Stem Cell Transplantation](https://scholariq.org/topics/hematopoietic-stem-cell-transplantation/)
- [Immune Cell Function and Interaction](https://scholariq.org/topics/immune-cell-function-and-interaction/)
- [T-cell and B-cell Immunology](https://scholariq.org/topics/t-cell-and-b-cell-immunology/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

## Researcher university

- [University of Minnesota](https://scholariq.org/institutions/university-of-minnesota/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.